Christine Rabinak, PhD, MBA

@brainsbeesbikes.bsky.social

Associate Dean for Research, Wayne State University Eugene Applebaum College of Pharmacy & Health Sciences Professor, Pharmacy Practice, Wayne State University Director, tnp2lab.org Psychiatric Neuroscience, Cannabinoids, Neuroimaging, Equestrian

New research from WSU researchers explored how movement competency, hip mobility, strength, and turnout interact in collegiate dancers. Results suggest motor control may play a key role in turnout performance and injury prevention. #EACPHS #PhysicalTherapy #DanceMedicine doi.org/10.1177/1089...

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

doi.org

Researchers at WSU EACPHS evaluated the transition from argatroban to warfarin in patients with heparin-induced thrombocytopenia. Challenges with transition success and suggest bleeding may be a greater concern than thrombosis during treatment transitions. doi.org/10.1007/s112...

Evaluation of argatroban to warfarin transition process in heparin-induced thrombocytopenia - Journal of Thrombosis and Thrombolysis

The argatroban to warfarin transition in heparin-induced thrombocytopenia (HIT) is complicated as argatroban falsely elevates the international normalized ratio. The evaluation aims were to assess compliance with institutional guidelines for this transition and transition success. This was a retrospective, single-system, observational cohort study of confirmed HIT patients receiving argatroban with the goal of warfarin transition between January-2019 and June-2024. Data collection included demographics, anticoagulant dosing, venous and arterial thromboses, major and clinically relevant non-major bleeding (CRNMB), and laboratory data. The primary endpoint was compliance with all eight steps of institutional guidelines. Secondary endpoints included individual compliance steps and transition success (defined as completion within seven days and absence of bleeding, thrombosis, non-therapeutic international normalized ratios (INRs) and argatroban restarts). A Fisher’s Exact test assessed the relationship between compliance and outcomes, significance at p < 0.05. Thirty-two argatroban to warfarin courses were evaluated in 29 patients. Compliance occurred in 10/32 (31.3%) of courses. Non-compliance was often due to failure to perform a two-step argatroban discontinuation process with doses > 2 mcg/kg/min (6/14, 42.9%). Transition success occurred in 50% (16/32) of courses. An extended bridge (argatroban and warfarin co-therapy) beyond seven days was the most common reason for failure in 29% (9/31). Bleeding (major and CRNMB) and thrombosis occurred in 18.8% and 6.3% of courses, respectively. There was no relationship between compliance and outcomes. The process for transitioning HIT patients from argatroban to warfarin is complex. The low rate of compliance and transition success highlights the challenging nature of this transition. Graphical Abstract A single center retrospective study assessed outcomes in 32 argatroban to warfarin transition courses in heparin-induced thrombocytopenia. Compliance with institution guidelines for the transition and transition success were low. Bleeding was a greater concern than thrombosis. Future areas of research were identified.

doi.org

Researchers at WSU EACPHS contributed to a study showing that most VTE patients complete the full DOAC high-intensity treatment period after parenteral anticoagulation. Bleeding risk and insurance coverage were important factors in treatment decisions. doi.org/10.1007/s112...

Practice patterns of DOAC high-intensity period following parenteral lead-in treatment for venous thromboembolism - Journal of Thrombosis and Thrombolysis

In the acute care setting, consensus is lacking on whether patients initially treated with parenteral anticoagulation for venous thromboembolism (VTE) should complete the full high-intensity period (HIP) of apixaban or rivaroxaban. This study examines HIP prescribing patterns following parenteral anticoagulation and assesses the influence of patient, provider, and facility characteristics. Patients initiating rivaroxaban or apixaban for VTE after parenteral anticoagulation were identified from the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) database between November 2015 and March 2024. Those with an indeterminate duration of parenteral treatment were excluded. Patients were categorized into full HIP and shortened HIP cohorts based on DOAC dose and duration. Demographics and comorbidities were compared using Student’s t-test and Chi-squared or Fisher’s exact tests. Variables with p < 0.3 were included in a logistic regression model, with stepwise selection at a 0.1 significance threshold. Among 816 patients, 687 (84.2%) received the full HIP, while 129 (15.8%) had a shortened HIP. Patients with private insurance (OR 0.3 [0.11–0.82], p = 0.02) or Medicare (OR 0.31 [0.11–0.92], p = 0.04) were less likely to receive a shortened HIP than Medicaid patients. Higher HAS-BLED scores were associated with increased odds of receiving a shortened HIP (OR 1.32 [1.1–1.59], p = 0.003). Provider type did not significantly impact HIP prescribing patterns. Despite prior parenteral anticoagulation, most patients completed the full DOAC HIP. Further research is needed to assess how patient, provider, and facility factors influence decision-making and to evaluate the impact of these decisions on clinical outcomes. Graphical abstract

doi.org

How can hospitals safely transition patients from apixaban or rivaroxaban to unfractionated heparin? A new review highlights the risks of anticoagulant stacking and offers recommendations to help optimize anticoagulation transitions and improve patient safety. WSU EACPHS doi.org/10.1093/ajhp...

Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy

AbstractPurpose. Hospitalized patients taking direct factor Xa inhibitors (DFXaIs), such as apixaban and rivaroxaban, often need to be transitioned to unfr

doi.org

New research shows semaglutide led to greater weight loss and HbA1c reduction than dulaglutide in real‑world patients with type 2 diabetes. Important contribution including a predominantly African American patient population. WSU EACPHS doi.org/10.37765/ajm...

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes | AJMC

In this real-world study of patients with type 2 diabetes, treatment with semaglutide resulted in greater reductions in body weight and hemoglobin A1c than dulaglutide.

doi.org